Envista (NYSE:NVST) Shares Up 5.6% – Still a Buy?

Envista Holdings Corporation (NYSE:NVST)’s share price was up 5.6% on Wednesday . The company traded as high as $21.80 and last traded at $21.7690. Approximately 530,669 shares were traded during trading, a decline of 78% from the average daily volume of 2,368,679 shares. The stock had previously closed at $20.62.

Analyst Upgrades and Downgrades

Several research firms recently commented on NVST. Barclays started coverage on Envista in a research note on Monday. They set an “overweight” rating and a $24.00 target price for the company. Stifel Nicolaus set a $25.00 price objective on shares of Envista in a research note on Thursday, October 30th. Zacks Research cut Envista from a “strong-buy” rating to a “hold” rating in a report on Monday, September 15th. Wall Street Zen upgraded shares of Envista from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 1st. Finally, Evercore ISI reaffirmed an “outperform” rating on shares of Envista in a research note on Friday, October 31st. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, eight have issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, Envista currently has an average rating of “Hold” and a consensus target price of $21.54.

Envista Stock Up 5.0%

The company has a market capitalization of $3.56 billion, a PE ratio of 241.24, a PEG ratio of 0.98 and a beta of 1.02. The company has a debt-to-equity ratio of 0.47, a quick ratio of 2.02 and a current ratio of 2.37. The stock’s 50 day moving average is $20.08 and its 200 day moving average is $20.05.

Envista (NYSE:NVST) last posted its earnings results on Wednesday, October 29th. The company reported $0.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.27 by $0.05. The firm had revenue of $669.90 million for the quarter, compared to the consensus estimate of $639.49 million. Envista had a return on equity of 5.90% and a net margin of 0.58%.The business’s quarterly revenue was up 11.5% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.12 earnings per share. On average, sell-side analysts anticipate that Envista Holdings Corporation will post 1 EPS for the current fiscal year.

Hedge Funds Weigh In On Envista

A number of large investors have recently modified their holdings of the company. Profit Investment Management LLC grew its position in Envista by 36.2% during the second quarter. Profit Investment Management LLC now owns 173,788 shares of the company’s stock worth $3,396,000 after buying an additional 46,191 shares in the last quarter. Pzena Investment Management LLC grew its holdings in shares of Envista by 7.2% during the second quarter. Pzena Investment Management LLC now owns 2,459,082 shares of the company’s stock worth $48,050,000 after purchasing an additional 164,825 shares in the last quarter. Strs Ohio bought a new position in shares of Envista in the first quarter worth approximately $1,433,000. First Hawaiian Bank raised its stake in Envista by 47.4% in the first quarter. First Hawaiian Bank now owns 47,597 shares of the company’s stock valued at $822,000 after purchasing an additional 15,312 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC lifted its position in Envista by 39.5% during the second quarter. Wealth Enhancement Advisory Services LLC now owns 66,018 shares of the company’s stock valued at $1,346,000 after purchasing an additional 18,699 shares during the last quarter.

Envista Company Profile

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.